Skip to Main Content

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a mid-stage clinical trial.

Taken by patients within one hour of a swelling attack, the KalVista pill, called KVD900, relieved symptoms quickly so that only 15% of attacks required the use of rescue medications within 12 hours compared with 30% of the attacks treated with a placebo pill. The difference was statistically significant, meeting the primary goal of the study, the company said.


Today, patients with hereditary angioedema rely on injectable medicines to quickly curb the pain and swelling brought on by recurrent disease flareups. KalVista’s goal is to develop KVD900 as a more convenient oral treatment option.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!